due to the decreased permeability effect of bevacizumab. Dr. Chamberlain suggests that this decreased incidence of pseudoprogression did not appear to diminish OS, which he primarily attributes to the impact of MGMT promoter methylation in patients. That is an interesting hypothesis but in our view, inflammatory response is vital to the synergism between radiation therapy and temozolomide chemotherapy. In the study by Lai et al., 5 up-front bevacizumab did decrease OS (albeit, not significantly) from 21.1 months to 19.6 months. This effect was particularly apparent in patients under 50 years old and with lower recursive partitioning analysis class, 5 groups who typically have the best outcomes in GBM trials.
CORRECTION

Vitamins B 12 , B 6 , and folic acid for cognition in older men
In the article "Vitamins B 12 , B 6 , and folic acid for cognition in older men" by A.H. Ford et al. (Neurology ® 2010; 75: 1540 -1547 , the daily dose of vitamin B 12 used in the trial was reported as 400 g, but should have been 500 g. The authors regret the error.
